In the fight against COVID-19, Indian pharmaceutical companies have made several announcements in recent months on treatments offering hope for patients while investors queued up to buy shares of these companies. However, India-China border dispute escalation may spell trouble for Indian pharma companies. China supplies around two-thirds of Indian pharmaceutical companies’ API needs, with some fermentation-based APIs and vitamins being entirely imported from China. So, how grave is the situation? Mint's Nasrin Sultana speaks to Surajit Pal, pharma analyst, Prabhudas Lilladher about the sector.
100 Episodes